Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer.

Shouksmith AE, Shah F, Grimard ML, Gawel JM, Raouf YS, Geletu M, Berger-Becvar A, de Araujo ED, Luchman HA, Heaton WL, Bakhshinyan D, Adile AA, Venugopal C, O'Hare T, Deininger MW, Singh SK, Konieczny SF, Weiss S, Fishel ML, Gunning PT.

J Med Chem. 2019 Mar 14;62(5):2651-2665. doi: 10.1021/acs.jmedchem.8b01957. Epub 2019 Mar 6.

PMID:
30776234
2.

Live-Cell Imaging Assays to Study Glioblastoma Brain Tumor Stem Cell Migration and Invasion.

Restall I, Bozek DA, Chesnelong C, Weiss S, Luchman HA.

J Vis Exp. 2018 Aug 29;(138). doi: 10.3791/58152.

3.

Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner.

Viswanath P, Radoul M, Izquierdo-Garcia JL, Luchman HA, Gregory Cairncross J, Pieper RO, Phillips JJ, Ronen SM.

Cancer Metab. 2018 Apr 3;6:3. doi: 10.1186/s40170-018-0178-3. eCollection 2018.

4.

2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas.

Viswanath P, Radoul M, Izquierdo-Garcia JL, Ong WQ, Luchman HA, Cairncross JG, Huang B, Pieper RO, Phillips JJ, Ronen SM.

Cancer Res. 2018 May 1;78(9):2290-2304. doi: 10.1158/0008-5472.CAN-17-2926. Epub 2018 Jan 22.

PMID:
29358170
5.
6.

Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1.

Mazor T, Chesnelong C, Pankov A, Jalbert LE, Hong C, Hayes J, Smirnov IV, Marshall R, Souza CF, Shen Y, Viswanath P, Noushmehr H, Ronen SM, Jones SJM, Marra MA, Cairncross JG, Perry A, Nelson SJ, Chang SM, Bollen AW, Molinaro AM, Bengtsson H, Olshen AB, Weiss S, Phillips JJ, Luchman HA, Costello JF.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10743-10748. doi: 10.1073/pnas.1708914114. Epub 2017 Sep 15.

7.

Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.

Chaumeil MM, Radoul M, Najac C, Eriksson P, Viswanath P, Blough MD, Chesnelong C, Luchman HA, Cairncross JG, Ronen SM.

Neuroimage Clin. 2016 Jun 23;12:180-9. doi: 10.1016/j.nicl.2016.06.018. eCollection 2016.

8.

Control of glioblastoma tumorigenesis by feed-forward cytokine signaling.

Jahani-Asl A, Yin H, Soleimani VD, Haque T, Luchman HA, Chang NC, Sincennes MC, Puram SV, Scott AM, Lorimer IA, Perkins TJ, Ligon KL, Weiss S, Rudnicki MA, Bonni A.

Nat Neurosci. 2016 Jun;19(6):798-806. doi: 10.1038/nn.4295. Epub 2016 Apr 25.

9.

Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.

Davis B, Shen Y, Poon CC, Luchman HA, Stechishin OD, Pontifex CS, Wu W, Kelly JJ, Blough MD; Terry Fox Research Institute Glioblastoma Consortium.

Neuro Oncol. 2016 Mar;18(3):350-60. doi: 10.1093/neuonc/nov143. Epub 2015 Aug 5.

10.

Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma Subtypes.

Cusulin C, Chesnelong C, Bose P, Bilenky M, Kopciuk K, Chan JA, Cairncross JG, Jones SJ, Marra MA, Luchman HA, Weiss S.

Stem Cell Reports. 2015 Jul 14;5(1):1-9. doi: 10.1016/j.stemcr.2015.05.010. Epub 2015 Jun 18.

11.

IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.

Izquierdo-Garcia JL, Viswanath P, Eriksson P, Cai L, Radoul M, Chaumeil MM, Blough M, Luchman HA, Weiss S, Cairncross JG, Phillips JJ, Pieper RO, Ronen SM.

Cancer Res. 2015 Aug 1;75(15):2999-3009. doi: 10.1158/0008-5472.CAN-15-0840. Epub 2015 Jun 4.

12.

Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.

Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Nov 15;20(22):5756-67. doi: 10.1158/1078-0432.CCR-13-3389. Epub 2014 Oct 14.

13.

Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.

Nguyen SA, Stechishin OD, Luchman HA, Lun XQ, Senger DL, Robbins SM, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Sep 15;20(18):4894-903. doi: 10.1158/1078-0432.CCR-13-1856. Epub 2014 Jul 30.

14.

Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma.

Haftchenary S, Luchman HA, Jouk AO, Veloso AJ, Page BD, Cheng XR, Dawson SS, Grinshtein N, Shahani VM, Kerman K, Kaplan DR, Griffin C, Aman AM, Al-Awar R, Weiss S, Gunning PT.

ACS Med Chem Lett. 2013 Sep 8;4(11):1102-7. doi: 10.1021/ml4003138. eCollection 2013 Nov 14.

15.

Prostate epithelium-specific deletion of the selenocysteine tRNA gene Trsp leads to early onset intraepithelial neoplasia.

Luchman HA, Villemaire ML, Bismar TA, Carlson BA, Jirik FR.

Am J Pathol. 2014 Mar;184(3):871-7. doi: 10.1016/j.ajpath.2013.11.025. Epub 2014 Jan 18.

16.

Lactate dehydrogenase A silencing in IDH mutant gliomas.

Chesnelong C, Chaumeil MM, Blough MD, Al-Najjar M, Stechishin OD, Chan JA, Pieper RO, Ronen SM, Weiss S, Luchman HA, Cairncross JG.

Neuro Oncol. 2014 May;16(5):686-95. doi: 10.1093/neuonc/not243. Epub 2013 Dec 22.

17.

Spontaneous loss of heterozygosity leading to homozygous R132H in a patient-derived IDH1 mutant cell line.

Luchman HA, Chesnelong C, Cairncross JG, Weiss S.

Neuro Oncol. 2013 Aug;15(8):979-80. doi: 10.1093/neuonc/not064. Epub 2013 Jun 11. No abstract available.

18.

On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.

Stechishin OD, Luchman HA, Ruan Y, Blough MD, Nguyen SA, Kelly JJ, Cairncross JG, Weiss S.

Neuro Oncol. 2013 Feb;15(2):198-207. doi: 10.1093/neuonc/nos302. Epub 2012 Dec 21.

19.

DNA hypermethylation and 1p Loss silence NHE-1 in oligodendroglioma.

Blough MD, Al-Najjar M, Chesnelong C, Binding CE, Rogers AD, Luchman HA, Kelly JJ, Fliegel L, Morozova O, Yip S, Marra M, Weiss S, Chan JA, Cairncross JG.

Ann Neurol. 2012 Jun;71(6):845-9. doi: 10.1002/ana.23610.

PMID:
22718548
20.

An in vivo patient-derived model of endogenous IDH1-mutant glioma.

Luchman HA, Stechishin OD, Dang NH, Blough MD, Chesnelong C, Kelly JJ, Nguyen SA, Chan JA, Weljie AM, Cairncross JG, Weiss S.

Neuro Oncol. 2012 Feb;14(2):184-91. doi: 10.1093/neuonc/nor207. Epub 2011 Dec 13.

21.

The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.

Luchman HA, Benediktsson H, Villemaire ML, Peterson AC, Jirik FR.

PLoS One. 2008;3(12):e3940. doi: 10.1371/journal.pone.0003940. Epub 2008 Dec 15.

22.

Temporally controlled prostate epithelium-specific gene alterations.

Luchman HA, Friedman HC, Villemaire ML, Peterson AC, Jirik FR.

Genesis. 2008 Apr;46(4):229-34. doi: 10.1002/dvg.20386.

PMID:
18395839
23.

Mgmt deficiency alters the in vivo mutational spectrum of tissues exposed to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).

Sandercock LE, Hahn JN, Li L, Luchman HA, Giesbrecht JL, Peterson LA, Jirik FR.

Carcinogenesis. 2008 Apr;29(4):866-74. doi: 10.1093/carcin/bgn030. Epub 2008 Feb 14.

PMID:
18281247
24.

Developmentally regulated cytoplasmic retention of the transcription factor XMI-ER1 requires sequence in the acidic activation domain.

Post JN, Luchman HA, Mercer FC, Paterno GD, Gillespie LL.

Int J Biochem Cell Biol. 2005 Feb;37(2):463-77.

PMID:
15474990
25.
26.

Elevated mutant frequencies and predominance of G:C to A:T transition mutations in Msh6(-/-) small intestinal epithelium.

Mark SC, Sandercock LE, Luchman HA, Baross A, Edelmann W, Jirik FR.

Oncogene. 2002 Oct 10;21(46):7126-30.

27.

Differential nuclear localization of ER1 protein during embryonic development in Xenopus laevis.

Luchman HA, Paterno GD, Kao KR, Gillespie LL.

Mech Dev. 1999 Jan;80(1):111-4.

28.

Supplemental Content

Loading ...
Support Center